Comparative Pharmacology
Head-to-head clinical analysis: PREVACID 24 HR versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID 24 HR versus PREVACID NAPRAPAC 250 COPACKAGED.
PREVACID 24 HR vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
15 mg orally once daily for 14 days.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination